If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

4D Pharma reports progress in bladder cancer trial

Fri, 27th May 2022 10:46

(Sharecast News) - Live biotherapeutics developer 4D Pharma announced progress in the phase 2 clinical trial in bladder cancer on Friday.

The AIM-traded firm said the trial was of 'MRx0518' in combination with 'Bavencio', or avelumab, a PD-L1 blocking antibody, as a first-line maintenance therapy for patients with unresectable locally advanced or metastatic urothelial carcinoma that had not progressed with first-line platinum-containing chemotherapy.

It said it was presenting a trial-in-progress poster at the 2022 American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

"We are continuing to build a strong body of evidence to support MRx0518 as a novel immunotherapy with broad potential to address significant unmet need across multiple oncology indications," said chief scientific officer Dr Alex Stevenson.

"MRx0518 has previously demonstrated single agent immuno-modulation of the tumour microenvironment, and this data supports the potential of this combination to significantly enhance and improve outcomes for patients beyond treatment with Bavencio alone."

Dr Stevenson said not only was the company able to evaluate MRx0518 with a leading immune checkpoint inhibitor, but was also able to assess its potential in earlier treatment settings.

"We are pleased to be sharing further details on the design of our first-line maintenance study with Bavencio for the treatment of locally advanced or metastatic urothelial carcinoma with the oncology medical community at ASCO."

At 1029 BST, shares in 4D Pharma were down 4.62% at 33p.

Reporting by Josh White at Sharecast.com.

More News
6 Jan 2020 08:42

4D Pharma To Trial MRx0518 For Pancreatic Cancer Treatment

4D Pharma To Trial MRx0518 For Pancreatic Cancer Treatment

Read more
6 Nov 2019 11:00

UK WINNERS & LOSERS SUMMARY: Vodafone Up, BT Down On Virgin Media Deal

UK WINNERS & LOSERS SUMMARY: Vodafone Up, BT Down On Virgin Media Deal

Read more
6 Nov 2019 09:36

4D Pharma Says MRx0518 and KEYTRUDA Combination Is Well Tolerated

4D Pharma Says MRx0518 and KEYTRUDA Combination Is Well Tolerated

Read more
5 Nov 2019 15:13

PRESS: Consortium Circles Healthcare Assets Of Fund Manager Woodford

PRESS: Consortium Circles Healthcare Assets Of Fund Manager Woodford

Read more
8 Oct 2019 10:35

WINNERS & LOSERS SUMMARY: Recruitment Firms Drop Amid Weak UK Market

WINNERS & LOSERS SUMMARY: Recruitment Firms Drop Amid Weak UK Market

Read more
8 Oct 2019 09:14

4d Pharma And Merck To Collaborate On Gut Disease Treatments

4d Pharma And Merck To Collaborate On Gut Disease Treatments

Read more
8 Oct 2019 08:30

4D Pharma inks research collaboration agreement with Merck & Co

(Sharecast News) - 4D Pharma has entered into a research collaboration agreement with Merck & Co to discover and develop live biotherapeutics for vaccines.

Read more
30 Sep 2019 09:33

4D Pharma Loss Deepens On Currency Headwinds As Pipeline Progresses

4D Pharma Loss Deepens On Currency Headwinds As Pipeline Progresses

Read more
27 Aug 2019 16:45

4D Pharma Appoints Sangamo Therapeutics Boss Macrae To Board

(Alliance News) - 4D Pharma PLC said Tuesday that it has appointed Sandy Macrae as an independent non-executive director with immediate effect.Macrae currently serves as president & of

Read more
25 Jul 2019 11:26

4d Pharma Picks New Candidate; Encouraging Data On Lead Biotherapeutic

(Alliance News) - 4d Pharma PLC on Thursday announced positive preclinical data on lead biotherapeutic candidate MRx0518 and the identification of a new candidate as well.The new candidate,

Read more
8 Jul 2019 09:29

4d Pharma Begins Live Biotherapeutics Asthma Programme

(Alliance News) - 4d Pharma PLC said Monday it has started a phase I/II study for its lead live biotherapeutic candidate for asthma.The double-blind, placebo-controlled study will enrol 90

Read more
13 Jun 2019 16:07

UK Shareholder Meetings Calendar - Next 7 Days

Friday 14 JuneMP Evans GroupSerabi GoldMonday 17 JuneChallenger 18

Read more
30 May 2019 14:26

DIRECTOR DEALINGS: 4d Pharma Chair Buys GBP15,000 In Shares

LONDON (Alliance News) - 4d Pharma PLC on Thursday said that Chair David Norwood acquired 15,000 shares in the company.On Wednesday, Norwood bought the shares at 100.00 pence each for a of

Read more
21 May 2019 11:27

4D Pharma losses widen as it spends cash on development activities

(Sharecast News) - Biotherapeutics development company 4D Pharma reported net assets of £45.8m in its final results on Tuesday, falling from £69.8m year-on-year.

Read more
21 May 2019 10:29

4d Pharma Annual Loss Widens On Live Biotherapeutic Development Costs

LONDON (Alliance News) - 4d Pharma PLC on Tuesday said its loss widened in 2018 on research and development costs as it continued to develop its live biotherapeutic products, which contain living

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.